Mid-Atlantic BioTherapeutics

A late-stage drug development company

OWNER

SERGE ROGOZHYN (See Profile)

Sector

Drug Discovery

Stage

Development, market readiness, clinical trial

Country

USA and EU holding will be created soon

The clinical trial in the Phase 3 and could be completed very fast and revenues are in 2 years.

IPO in 24 month.

Orphan drug designation for rabies. Could become the only company in the world with a treatment.

Patent

Status

Pending

IP Type

Patent

Time

–

Countries

USA

Coverage

Molecule

This information is confidential, do not share or copy.

You can visit their website or

Download the Pitch Deck

Under evaluation at least till: 25th of July 2023

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

Funding: 5.000.000$
Stage: Development, market readiness, clinical trial
Sector: Biotech
+

BioZen Limited

BioZen Limited Developing the world's first approved medica...
Funding: 500.000€
Stage: Development, market readiness, clinical trial
Sector: Medical Device
+

Laboratorios Isimo, SL

Laboratorios Isimo, SL Laboratorios Isimo, SL Medical Devic...

OWNER

Sector

Stage

Country

The clinical trial in the Phase 3 and could be completed very fast and revenues are in 2 years.

IPO in 24 month.

Orphan drug designation for rabies. Could become the only company in the world with a treatment.

This information is confidential, do not share or copy.

BioZen Limited

Laboratorios Isimo, SL

Capital Cell Barcelona

Links

About cookies

OWNER

Sector

Stage

Country

The clinical trial in the Phase 3 and could be completed very fast and revenues are in 2 years.

IPO in 24 month.

Orphan drug designation for rabies. Could become the only company in the world with a treatment.

This information is confidential, do not share or copy.

BioZen Limited

Laboratorios Isimo, SL

Capital Cell Barcelona

Links

About cookies

Log in with your credentials

Forgot your details?

Create Account